Cantor Fitzgerald has issued "strong-buy" ratings for multiple stocks, including Immunovant, Ardelyx, Kura Oncology, and Mesoblast. Meanwhile, Bank of America adjusts price targets for Gilead Sciences and Immunovant. Read more...